CA2473229A1 - Selective melanin-concentrating hormone type -1 receptor agonists - Google Patents

Selective melanin-concentrating hormone type -1 receptor agonists Download PDF

Info

Publication number
CA2473229A1
CA2473229A1 CA002473229A CA2473229A CA2473229A1 CA 2473229 A1 CA2473229 A1 CA 2473229A1 CA 002473229 A CA002473229 A CA 002473229A CA 2473229 A CA2473229 A CA 2473229A CA 2473229 A1 CA2473229 A1 CA 2473229A1
Authority
CA
Canada
Prior art keywords
mch
acid
peptide
present
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002473229A
Other languages
English (en)
French (fr)
Inventor
Maria A. Bednarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2473229A1 publication Critical patent/CA2473229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002473229A 2002-01-09 2003-01-06 Selective melanin-concentrating hormone type -1 receptor agonists Abandoned CA2473229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34719102P 2002-01-09 2002-01-09
US60/347,191 2002-01-09
PCT/US2003/000241 WO2003060091A2 (en) 2002-01-09 2003-01-06 Selective melanin-concentrating hormone type -1 receptor agonists

Publications (1)

Publication Number Publication Date
CA2473229A1 true CA2473229A1 (en) 2003-07-24

Family

ID=23362689

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002473229A Abandoned CA2473229A1 (en) 2002-01-09 2003-01-06 Selective melanin-concentrating hormone type -1 receptor agonists

Country Status (5)

Country Link
US (1) US7273846B2 (enExample)
EP (1) EP1495046A2 (enExample)
JP (1) JP2005527491A (enExample)
CA (1) CA2473229A1 (enExample)
WO (1) WO2003060091A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827217B2 (en) 2015-08-25 2017-11-28 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US9884813B1 (en) 2017-03-01 2018-02-06 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US12011427B2 (en) 2019-12-11 2024-06-18 Inspirna, Inc. Methods of treating cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1416951A1 (en) 2001-08-08 2004-05-12 Merck & Co., Inc. Melanin-concentrating hormone antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049655A (en) 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
US5849708A (en) * 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
CA2399509A1 (en) 2000-02-03 2001-08-09 Merck & Co., Inc. Melanin-concentrating hormone analogs
JP2004537521A (ja) 2001-05-31 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド メラニン濃縮ホルモン類似体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827217B2 (en) 2015-08-25 2017-11-28 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US10512623B2 (en) 2015-08-25 2019-12-24 Rgenix, Inc. Pharmaceutically acceptable salts of B-Guanidinopropionic acid with improved properties and uses thereof
US9884813B1 (en) 2017-03-01 2018-02-06 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US12011427B2 (en) 2019-12-11 2024-06-18 Inspirna, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
EP1495046A2 (en) 2005-01-12
JP2005527491A (ja) 2005-09-15
US7273846B2 (en) 2007-09-25
US20050020492A1 (en) 2005-01-27
WO2003060091A3 (en) 2004-11-04
WO2003060091A2 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
US7335723B2 (en) Melanin-concentrating hormone antagonists
US6967237B2 (en) Ghrelin analogs
AU2003259062B2 (en) Growth hormone releasing peptides
TWI325003B (en) Ghrelin analogs
HRP20030126A2 (en) Selective cyclic peptides
AU2002322466A1 (en) Linear and cyclic melanocortin receptor-specific peptides
CA2453515A1 (en) Linear and cyclic melanocortin receptor-specific peptides
US5854216A (en) Marker for growth hormone-releasing factor receptors
CN100425282C (zh) 用于治疗性干预的y2/y4选择性受体激动剂
US11124541B2 (en) Chimeric melanocortin ligands and methods of use thereof
US7273846B2 (en) Selective melanin-concentrating hormone type-1 receptor agonists
CA2399509A1 (en) Melanin-concentrating hormone analogs
US7314861B2 (en) Melanin-concentrating hormone analogs
US7220720B2 (en) Melanin-concentrating hormone analogs
WO2002024732A2 (en) Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
Kazantzis Solid-phase syntheses and studies of conformationally constrained analogues of the calcitonin gene peptide superfamily polypeptides calcitonin (Ct) and islet amyloid polypeptide (IAPP)

Legal Events

Date Code Title Description
FZDE Discontinued